Production (Stage)
Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 14.45M | 14.31M | 12.99M | 12.64M | 10.25M |
| Gross Profit | -14.45M | -14.31M | -12.99M | -12.64M | -10.25M |
| SG&A Expenses | 6.21M | 5.99M | 6.32M | 6.31M | 6.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.65M | 20.30M | 19.31M | 18.95M | 16.35M |
| Operating Income | -20.65M | -20.30M | -19.31M | -18.95M | -16.35M |
| Income Before Tax | -21.48M | -20.54M | -20.98M | -17.01M | -15.66M |
| Income Tax Expenses | 63.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.55 | -20.54 | -20.98 | -17.01 | -15.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.55M | -20.54M | -20.98M | -17.01M | -15.66M |
| EBIT | -20.65M | -20.30M | -19.31M | -18.95M | -16.35M |
| EBITDA | -20.64M | -20.29M | -19.31M | -18.94M | -16.34M |
| EPS Basic | -0.17 | -0.18 | -0.19 | -0.15 | -0.15 |
| Normalized Basic EPS | -0.09 | -0.10 | -0.10 | -0.09 | -0.09 |
| EPS Diluted | -0.17 | -0.18 | -0.19 | -0.15 | -0.15 |
| Normalized Diluted EPS | -0.09 | -0.10 | -0.10 | -0.09 | -0.09 |
| Average Basic Shares Outstanding | 512.15M | 459.11M | 451.41M | 451.17M | 416.55M |
| Average Diluted Shares Outstanding | 512.15M | 459.11M | 451.41M | 451.17M | 416.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |